文献速递系统性红斑狼疮

真实世界环境中狼疮肾炎患者疾病修饰的达成:不可能的任务?

Disease modification achievement in patients with lupus nephritis in a real-life setting: mission impossible?
PubMed 文献 · RMD Open · 2023-01-01

该研究在两家联合学术中心纳入活检证实的狼疮肾炎患者(82%为女性),随访≥72个月,评估疾病修饰(DM)达成情况。结果显示60%患者达成DM,排除糖皮质激素标准后升至70%;9个月时24小时蛋白尿可预测DM达成(OR 0.72,95%CI 0.53至0.97,p=0.03),未达成DM者长期肾脏结局更差。

要点

  • 真实世界中仅60%狼疮肾炎患者达成疾病修饰,排除糖皮质激素标准后为70%。
  • 9个月时24小时蛋白尿预测DM达成(OR 0.72,95%CI 0.53至0.97,p=0.03)。
  • 未达成DM者随访结束时肾脏结局(复发、蛋白尿增加>30%、eGFR下降)更差。

核心结论

  • 真实世界中仅60%狼疮肾炎患者达成DM,部分因未达到糖皮质激素剂量目标,DM失败与更差长期肾脏结局相关。

研究设计与样本

  • 在两家联合学术中心纳入活检证实的狼疮肾炎患者(82%为女性),随访≥72个月,收集临床、实验室及组织学起始队列数据。

主要发现

  • 60%患者达成DM,排除糖皮质激素标准后升至70%。
  • 9个月时24小时蛋白尿预测DM达成(OR 0.72,95%CI 0.53至0.97,p=0.03),基线特征均未预测DM达成。
  • 随访>72个月的患者中,未达成DM者随访结束时肾脏结局(复发、蛋白尿增加>30%、eGFR下降)较达成DM者更差(中位随访138个月)。
  • 1992至2005年诊断的患者较2006至2016年诊断者DM达成百分比显著更低(p=0.006),且在三个时间段均更少满足糖皮质激素剂量减少标准(p<0.01)。

关键数值与推荐

  • DM标准针对24小时蛋白尿、估算肾小球滤过率(eGFR)、肾脏复发和糖皮质激素剂量,在三个时间段(第0-12月、13-60月和第72月)设定。
  • 第一模型要求患者在三个时间段均满足全部四项标准方达成DM;第二模型排除持续的糖皮质激素减少标准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: A preliminary definition of disease modification (DM) in lupus nephritis (LN) was recently developed focusing on long-term remission and damage prevention, with minimal treatment-associated toxicity. We aimed to further specify aspects of DM criteria in LN, assess DM achievement in a real-world setting and examine potential DM predictors and long-term outcomes. METHODS: We collected clinical/laboratory and histological inception cohort data from biopsy-proven LN patients (82% females) with ≥72 months follow-up at two joint academic centres. Specific criteria for 24-hour proteinuria, estimated glomerular filtration rate (eGFR), renal flares and glucocorticoids dose were set at three time frames (months 0-12, 13-60 and 72) to assess DM. In the first model, DM was achieved if patients fulfilled all four criteria at all three time frames (achievers). In the second model, the continued glucocorticoids reduction criterion was excluded. Logistic regression analyses were performed. Possible different trends in DM achievement between past and recent decades were also investigated. RESULTS: DM was achieved by 60% of patients, increased to 70% when glucocorticoids excluded from DM criteria. 24-hour proteinuria at 9 months predicted DM achievement (OR 0.72, 95% CI 0.53 to 0.97, p=0.03), but none of baseline characteristics. Among patients with >72 month follow-up, non-achievers had worse renal outcomes (flares, >30% proteinuria increase, eGFR decline) than achievers at the end of follow-up (median 138 months). Patients diagnosed between 1992 and 2005 were found to have significantly lower percentages of DM achievement and met less often the glucocorticoids dose reduction criterion in all three time frames, compared with those diagnosed between 2006 and 2016 (p=0.006 and p<0.01, respectively). CONCLUSIONS: DM was achieved by only 60% of LN patients in a real-life setting, partly due to lack of glucocorticoids dose target attainment, while DM failure was associated with worse long-term renal outcomes. This may imply limitations in the effectiveness or implementation of current LN treatments, supporting the need for novel therapeutic strategies.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Panagiotopoulos A, Kapsia E, Michelakis I, et al. Disease modification achievement in patients with lupus nephritis in a real-life setting: mission impossible? RMD Open. 2023. PMID: 37308249. doi:10.1136/rmdopen-2023-003158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。